{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-011002","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2023-01-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.557730+00:00","generated_at":"2026-06-20T13:11:22.881461+00:00","sec_items":["3.02","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Cullinan Oncology exchanges 6.5M common shares for Series A convertible preferred held by BVF funds","bullets":["Exchanged 6,475,000 common shares for 647,500 Series A convertible preferred (10:1 conversion ratio).","Issued under Section 3(a)(9) exemption; no commissions paid.","Preferred shares have no voting rights; conversion limited to initial 9.99% beneficial ownership cap.","Post-exchange common outstanding: 39,324,370; preferred convertible into up to 6,457,000 common shares.","Transaction closed Jan 19, 2023 with Biotechnology Value Fund L.P. and affiliates."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-011002","json":"https://secwatch.observer/filing/0001193125-23-011002.json","markdown":"https://secwatch.observer/filing/0001193125-23-011002.md","text":"https://secwatch.observer/filing/0001193125-23-011002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000119312523011002/0001193125-23-011002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000119312523011002/d399356d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T13:11:22.881461+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}